1. Introduction {#sec1-molecules-17-13642}
===============

In previous work, we have found that certain substituted pyridines and their derivatives showed antimicrobial, analgesic, anticonvulsant, antiparkinsonian \[[@B1-molecules-17-13642],[@B2-molecules-17-13642],[@B3-molecules-17-13642],[@B4-molecules-17-13642]\] and antitumor activities \[[@B5-molecules-17-13642],[@B6-molecules-17-13642],[@B7-molecules-17-13642]\]. In addition, the biological and analgesic activities of many heterocyclic compounds containing a sulfur atom have been reviewed \[[@B8-molecules-17-13642],[@B9-molecules-17-13642],[@B10-molecules-17-13642]\]. On the other hand, thienopyrimidine and thioxopyrimidine derivatives have promising biological \[[@B11-molecules-17-13642],[@B12-molecules-17-13642]\] and anticancer activity \[[@B13-molecules-17-13642]\]. Recently, some new oxazinones, thienopyrimidinones and their derivatives have been synthesized as anti-inflammatory, antimicrobial and anti-HIV agents \[[@B14-molecules-17-13642],[@B15-molecules-17-13642],[@B16-molecules-17-13642],[@B17-molecules-17-13642],[@B18-molecules-17-13642]\]. In view of these observations and in continuation of our previous work in pyridine chemistry, we have now synthesized some novel heterocyclic compounds containing the thieno\[2,3-*b*\]pyridine moiety fused with a pyridine, oxazinone, or pyrimidinone, nucleus and tested their antimicrobial activities.

2. Results and Discussion {#sec2-molecules-17-13642}
=========================

2.1. Synthesis {#sec2dot1-molecules-17-13642}
--------------

The starting materials **3a**--**c** ([Table 1](#molecules-17-13642-t001){ref-type="table"}) were prepared from 2,6-dihydroxyisonicotinic acid (**1**) via the corresponding 2-chloro-6-ethoxy-4-acetylpyridine **2** according to literature methods \[[@B1-molecules-17-13642],[@B19-molecules-17-13642]\]. Acryloyl derivatives **3a**--**c** were condensed with 2-cyanothioacetamide in the presence of ammonium acetate to give the corresponding cyanopyridine thione derivatives **4a**--**c** ([Table 1](#molecules-17-13642-t001){ref-type="table"}). Treatment of **4a**--**c** with ethyl chloroacetate in the presence of anhydrous K~2~CO~3~ gave the corresponding ethyl ester derivative **5a**--**c** ([Table 1](#molecules-17-13642-t001){ref-type="table"}), which were cyclized by sodium methoxide in methanol to give the amino ester derivatives **6a**--**c** ([Table 1](#molecules-17-13642-t001){ref-type="table"}). Aminolysis of compounds **6a**--**c** by action of ammonia gas afforded the corresponding aminoamide derivatives **7a**--**c** ([Scheme 1](#molecules-17-13642-sch001){ref-type="scheme"}, [Table 1](#molecules-17-13642-t001){ref-type="table"}). The IR spectra of **6a**--**c** showed the absence of ν (C≡N) for **5a**--**c** and the presence of broad band corresponding to ν (NH~2~). Also, the IR spectra of **7a**--**c** showed the absence of ν(C=O, ester) for **6a**--**c** and the presence of a broad band corresponding to ν(NH~2~).

Compounds **6a**--**c** were hydrolyzed by refluxing with ethanolic sodium hydroxide (NaOH) to the corresponding sodium salts **8a**--**c**, which was treated *in situ* with refluxing acetic anhydride to give the corresponding oxazinone derivatives **9a**--**c** ([Table 2](#molecules-17-13642-t002){ref-type="table"}). Reaction of **9a**--**c** with ammonium acetate in refluxing acetic acid afforded the corresponding pyrimidinone derivatives **10a**--**c** ([Table 2](#molecules-17-13642-t002){ref-type="table"}), which were treated with methyl iodide in *N,N-*dimethylformamide in the presence of anhydrous K~2~CO~3~ to yield the corresponding 3-methyl-pyrimidinone derivatives **11a**--**c** ([Scheme 2](#molecules-17-13642-sch002){ref-type="scheme"}, [Table 2](#molecules-17-13642-t002){ref-type="table"}).

2.2. Antimicrobial Activity {#sec2dot2-molecules-17-13642}
---------------------------

The antimicrobial activities of some of the synthesized compounds were determined by the agar diffusion method as recommended by the National Committee for Clinical Laboratory Standards (NCCLS) \[[@B20-molecules-17-13642]\]. The compounds were evaluated for antimicrobial activity against bacteria, *viz*. *Streptomyces* sp., *Bacillus subtilis*, *Streptococcus lactis*, *Escherichia coli*, and *Pseudomonas* sp. and antifungal activity against various fungi, *viz*. *Aspergillus niger*, *Penicillium* sp and yeast *Candida albican* and *Rhodotorula ingeniosa*.

The concentrations of the tested compounds (10 µg/mL) were used according to a modified Kirby-Bauer's disk diffusion method. The sterile discs were impregnated with 10 µg/disc of the tested compound. Each tested compound was performed in triplicate. The solvent DMSO was used as a negative control and streptomycin/fusidic acid were used as standard calculated average diameters (for triplicates) of the zone of inhibition (in mm) for tested samples with that produced by the standard drugs. Four of the synthesized compounds **5a**, **7b**, **9b** and **10b** exhibited potent antibacterial and antifungal bioactivity compared with the standard drug used. The other tested compounds were found to exhibit a moderate to low antibacterial activity ([Table 3](#molecules-17-13642-t003){ref-type="table"}).

On the other hand, when different concentrations of compound **9a** were used, it was exhibited a moderate antibacterial activity, but it exhibited very good antibacterial activity at higher concentrations (3× and 4×) ([Table 4](#molecules-17-13642-t004){ref-type="table"}), while different concentrations of compounds **5a** and **10a** exhibited very good antifungal activities (2× and 3×) ([Table 5](#molecules-17-13642-t005){ref-type="table"}).

3. Experimental {#sec3-molecules-17-13642}
===============

3.1. Chemistry {#sec3dot1-molecules-17-13642}
--------------

Melting points were measured using Electrothermal 9100 digital melting point apparatus (Electrothermal, Essex, UK) and are uncorrected. IR spectra were recorded on a Perkin-Elmer 1600 FTIR (Perkin-Elmer, Downers Grove, IL, USA) in KBr discs. ^1^H- and ^13^C-NMR spectra were measured on a Jeol 5000 MHz spectrometer (Jeol, Tokyo, Japan) in DMSO-*d*~6~, and chemical shifts were recorded in δ ppm relative to the internal standard TMS. The Mass spectra were run at 70 eV with a Finnigan SSQ 7000 spectrometer (Madison, WI, USA) using EI and the values of *m/z* are indicated in Dalton. Elemental analyses were performed on a Perkin-Elmer 2400 analyzer (Perkin-Elmer) and were found within ±0.4% of the theoretical values. All reactions were followed by *TLC* (Silica gel, Aluminum Sheets 60 F~254~, Merck, Darmstadt, Germany). Starting material **2** was prepared from citrazinic acid (**1**) according to published procedures \[[@B1-molecules-17-13642],[@B19-molecules-17-13642]\]. Antimicrobial screening was carried out in Department of Microbial Chemistry, National Research Center, Cairo, Egypt.

*1-(2-Chloro-6-ethoxypyridin-4-yl)-3-(substituted phenyl)prop-2-en-1-ones* **3a**--**c**. A mixture of 2-chloro-6-ethoxy-4-acetylpyridine (**2**) \[[@B19-molecules-17-13642]\] (1 mmol) and an aromatic aldehyde, namely, 4-flouro-, 4-chloro- or 2,4-dichlorobenzaldehyde (1 mmol) in absolute ethanol (30 mL) was refluxed in the presence of a mixture of TEA/DEA (3 mL, 1:1 v:v) for 6 h. The reaction mixture was concentrated under reduced pressure, the obtained solid was filtered off, washed with ether, dried and crystallized from the proper solvents to afford the corresponding acryloyl derivatives **3a**--**c**, respectively.

*1-(2-Chloro-6-ethoxypyridin-4-yl)-3-(4-fluorophenyl)prop-2-en-1-one* (**3a**). IR (KBr, cm^−1^): ν 1679 (C=O), 1607 (C=C); ^1^H-NMR: δ 1.32 (t, 3H, CH~3~, *J* = 6.95 Hz), 3.81 (q, 2H, CH~2~, *J* = 6.95 Hz), 6.65 (d, 1H, CH-olefinic-H, *J* = 14.60 Hz), 6.98 (d, 1H, CH-olefinic-H, *J* = 14.60 Hz), 7.28--7.96 (m, 6H, 4 Ph-H + 2 pyr-H); ^13^C-NMR: 13.68, 64.32, 104.95, 109.56, 114.72, 121.30, 129.86, 130.05, 144.65, 145.84, 146.50, 160.95, 164.96, 186.50; MS, *m/z* (%): 306 (M^+^, 15), 184 (100); Elemental analysis for C~16~H~13~ClFNO~2~ (305.73): calcd.: C, 62.86; H, 4.29; Cl, 11.60; N, 4.58. found: C, 62.80; H, 4.26; Cl, 11.55; N, 4.52.

*1-(2-Chloro-6-ethoxypyridin-4-yl)-3-(4-chlorophenyl)prop-2-en-1-one* (**3b**). IR (KBr, cm^−1^): ν 1682 (C=O), 1610 (C=C); ^1^H-NMR: δ 1.33 (t, 3H, CH~3~, *J* = 6.95 Hz), 3.92 (q, 2H, CH~2~, *J* = 6.95 Hz), 6.58 (d, 1H, CH-olefinic-H, *J* = 14.60 Hz), 7.05 (d, 1H, CH-olefinic-H, *J* = 14.60 Hz), 7.12--7.88 (m, 6H, 4 Ph-H + 2 pyr-H); ^13^C-NMR: 13.86, 64.26, 105.78, 109.62, 121.12, 126.86, 128.25, 132.85, 132.96, 144.68, 145.78, 146.65, 164.84, 186.86; MS, *m/z* (%): 322 (M^+^, 8), 165 (100); Elemental analysis for C~16~H~13~Cl~2~NO~2~ (322.18): calcd.: C, 59.65; H, 4.07; Cl, 22.01; N, 4.35. found: C, 59.60; H, 4.00; Cl, 21.96; N, 4.30.

*1-(2-Chloro-6-ethoxypyridin-4-yl)-3-(2,4-dichlorophenyl)prop-2-en-1-one* (**3c**). IR (KBr, cm^−1^): ν 1678 (C=O), 1612 (C=C); ^1^H-NMR: δ 1.28 (t, 3H, CH~3~, *J* = 6.95 Hz), 3.86 (q, 2H, CH~2~, *J* = 6.95 Hz), 6.46 (d, 1H, CH-olefinic-H, *J* = 14.60 Hz), 7.10 (d, 1H, CH-olefinic-H, *J* = 14.60 Hz), 7.25--7.76 (m, 5H, 3 Ph-H + 2 pyr-H); ^13^C-NMR: 13.92, 64.30, 105.96, 109.46, 121.21, 125.69, 128.78, 129.56, 130.85, 132.05, 133.65, 144.86, 145.88, 146.54, 164.78, 187.05; MS, *m/z* (%): 356 \[M^+^,10\], 199 \[100, base peak\]; Elemental analysis for C~16~H~1~2Cl~3~NO2 (356.63): calcd.: C, 53.89; H, 3.39; Cl, 29.82; N, 3.93. found: C, 53.83; H, 3.34; Cl, 29.80; N, 3.88.

*6-(2-Chloro-6-ethoxypyridin-4-yl)-4-(substituted phenyl)-1,2-dihydro-2-thioxopyridine-3-carbonitriles* **4a**--**c**. A mixture of **3a**--**c** (1 mmol), 2-cyanothioacetamide (0.10 g, 1 mmol) and ammonium acetate (0.6 g, 8 mmol) in absolute ethanol (30 mL) was refluxed for 5 h. After cooling, the formed product was collected by filtration, washed with ethanol, dried and crystallized from the proper solvents to give the corresponding thioxopyridine derivatives **4a**--**c**, respectively.

*6-(2-Chloro-6-ethoxypyridin-4-yl)-4-(4-fluorophenyl)-1,2-dihydro-2-thioxopyridine-3-carbonitrile* (**4a**). IR (KBr, cm^−1^): ν 3330 (NH), 2210 (CN), 1218 (C=S); ^1^H-NMR: δ 1.30 (t, 3H, CH~3~, *J* = 6.95 Hz), 3.90 (q, 2H, CH~2~, *J* = 6.95 Hz), 6.95--7.78 (m, 6H, 4 Ph-H + 2 pyr-H), 8.46 (s, 1H, pyr-5\'-H), 9.24 (s, 1H, NH exchangeable with D~2~O); ^13^C-NMR: 13.66, 63.98, 103.66, 103.88, 107.89, 108.55, 114.58, 116.02, 127.50, 128.04, 145.48, 148.60, 160.56, 161.76, 164.65, 167.47, 168.05; MS, *m/z* (%): 386 \[M^+^,24\], 135 \[100, base peak\]; Elemental analysis for C~19~H~13~ClFN~3~OS (385.84): calcd.: C, 59.14; H, 3.40; Cl, 9.19; N, 10.89; S, 8.31. found: C, 59.10; H, 3.35; Cl, 9.14; N, 10.85; S, 8.28.

*6-(2-Chloro-6-ethoxypyridin-4-yl)-4-(4-chlorophenyl)-1,2-dihydro-2-thioxopyridine-3-carbonitrile* (**4b**). IR (KBr, cm^−1^): ν 3356 (NH), 2215 (CN), 1210 (C=S); ^1^H-NMR: δ 1.34 (t, 3H, CH~3~, *J* = 6.95 Hz), 3.86 (q, 2H, CH~2~, *J* = 6.95 Hz), 7.12--7.80 (m, 6H, 4 Ph-H + 2 pyr-H), 8.52 (s, 1H, pyr-5\'-H), 9.18 (s, 1H, NH exchangeable with D~2~O); ^13^C-NMR: 13.92, 64.12, 103.96, 104.04, 108.14, 108.86, 115.82, 127.66, 128.10, 129.68, 132.67, 145.56, 148.72, 160.77, 164.58, 167.55, 167.86; MS, *m/z* (%): 402 \[M^+^,32\], 211 \[100, base peak\]; Elemental analysis for C~19~H~13~Cl~2~N~3~OS (402.29): calcd.: C, 56.73; H, 3.26; Cl, 17.63; N, 10.45; S, 7.97. found: C, 56.68; H, 3.20; Cl, 17.60; N, 10.40; S, 7.92.

*6-(2-Chloro-6-ethoxypyridin-4-yl)-4-(2,4-dichlorophenyl)-1,2-dihydro-2-thioxopyridine-3-carbonitrile* (**4c**). ν 3348 (NH), 2218 (CN), 1212 (C=S); ^1^H-NMR: δ 1.32 (t, 3H, CH~3~, *J* = 6.95 Hz), 3.78 (q, 2H, CH~2~, *J* = 6.95 Hz), 6.98--7.68 (m, 5H, 3 Ph-H + 2 pyr-H), 8.64 (s, 1H, pyr-5\'-H), 9.34 (s, 1H, NH exchangeable with D~2~O); ^13^C-NMR: 14.14, 64.18, 103.88, 104.08, 108.22, 108.92, 115.76, 125.98, 128.56, 129.16, 131.86, 132.15, 134.86, 145.64, 148.80, 161.24, 164.32, 167.45, 168.18; MS, *m/z* (%): 436 \[M^+^,14\], 279 \[100, base peak\]; Elemental analysis for C~19~H~12~Cl~3~N~3~OS (436.74): calcd.: C, 52.25; H, 2.77; Cl, 24.35; N, 9.62; S, 7.34. found: C, 52.20; H, 2.71; Cl, 24.30; N, 9.57; S, 7.28.

*Ethyl 2-(6-(2-chloro-6-ethoxypyridin-4-yl)-3-cyano-4-(substituted phenyl)pyridin-2-ylthio)acetates* **5a**--**c***.* To a mixture of **4a**--**c** (1 mmol) and anhydrous K~2~CO~3~ (0.18 g, 1 mmol) in *N*-dimethylformamide (25 mL) was stirred at room temperature for 2 h, ethyl chloroacetate (0.18 g, 1.5 mmol) was added with stirring. The reaction mixture was heated at 60 °C for 2 h and after cooling poured into ice. The solid formed was collected by filtration, washed with water, dried and crystallized from the proper solvents to afford the corresponding pyridinethioacetate derivatives **5a**--**c**, respectively.

*Ethyl 2-(6-(2-chloro-6-ethoxypyridin-4-yl)-3-cyano-4-(4-fluorophenyl)pyridin-2-ylthio)acetate* (**5a**). IR (KBr, cm^−1^): ν 2219 (CN), 1735 (C=O, ester); ^1^H-NMR: δ 1.28, 1.32 (2t, 6H, 2 CH~3~), 3.68, 3.86 (2q, 4H, 2 CH~2~), 4.38 (s, 2H, S--CH~2~), 7.16--7.82 (m, 6H, 4 Ph-H + 2 pyr-H), 8.18 (s, 1H, pyr-5\'-H); ^13^C-NMR: 13.65, 14.05, 32.04, 59.86, 64.08, 101.36, 101.57, 102.85, 115.02, 116.75, 117.02, 128.74, 132.58, 145.65, 151.56, 153.65, 157.08, 162.15, 163.56, 163.94, 168.90; MS, *m/z* (%): 472 \[M^+^,12\], 426 \[100, base peak\]; Elemental analysis for C~23~H~19~ClFN~3~O~3~S (471.93): calcd.: C, 58.54; H, 4.06; Cl, 7.51; N, 8.90; 17; S, 6.79. found: C, 58.48; H, 4.00; Cl, 7.45; N, 8.84; 17; S, 6.72.

*Ethyl 2-(6-(2-chloro-6-ethoxypyridin-4-yl)-3-cyano-4-(4-chlorophenyl)pyridin-2-ylthio)acetate* (**5b**). IR (KBr, cm^−1^): ν 2222 (CN), 1732 (C=O, ester); ^1^H-NMR: δ 1.29, 1.32 (2t, 6H, 2 CH~3~), 3.56, 3.84 (2q, 4H, 2 CH~2~), 4.42 (s, 2H, S--CH~2~), 7.10--7.72 (m, 6H, 4 Ph-H + 2 pyr-H), 8.64 (s, 1H, pyr-5\'-H); ^13^C-NMR: 13.78, 14.15, 32.18, 60.05, 64.18, 101.48, 101.68, 102.74, 116.88, 117.02, 127.54, 128.12, 129.57, 133.45, 145.56, 150.96, 153.64, 157.18, 163.72, 164.05, 170.04; MS, *m/z* (%): 488 \[M^+^,32\], 120 \[100, base peak\]; Elemental analysis for C~23~H~19~Cl~2~N~3~O~3~S (488.38): calcd.: C, 56.56; H, 3.92; Cl, 14.52; N, 8.60; S, 6.57. found: C, 56.50; H, 3.88; Cl, 14.47; N, 8.55; S, 6.51.

*Ethyl 2-(6-(2-chloro-6-ethoxypyridin-4-yl)-3-cyano-4-(2,4-dichlorophenyl)pyridin-2-ylthio)acetate* (**5c**). IR (KBr, cm^−1^): ν 2218 (CN), 1735 (C=O, ester); ^1^H-NMR: δ 1.26, 1.30 (2t, 6H, 2 CH~3~), 3.58, 3.78 (2q, 4H, 2 CH~2~), 4.36 (s, 2H, S--CH~2~), 7.12--7.65 (m, 5H, 3 Ph-H + 2 pyr-H), 8.56 (s, 1H, pyr-5\'-H); ^13^C-NMR: 13.84, 14.18, 32.18, 59.92, 64.18, 100.98, 101.59, 102.66, 116.82, 117.06, 125.86, 128.48, 129.24, 131.92, 132.24, 134.74, 145.58, 151.08, 153.72, 157.22, 163.88, 164.15, 168.84; MS, *m/z* (%): 523 \[M^+^,8\], 247 \[100, base peak\]; Elemental analysis for C~23~H~18~Cl~3~N~3~O~3~S (522.83): C, 52.84; H, 3.47; Cl, 20.34; N, 8.04; S, 6.13. found: C, 52.78; H, 3.40; Cl, 20.28; N, 8.00; S, 6.07.

*Ethyl 3-amino-6-(2-chloro-6-ethoxypyridin-4-yl)-4-(substituted phenyl)thieno\[2,3-b\]pyridine-2-carboxylates* **6a**--**c**. A mixture of **5a**--**c** (1 mmol) in sodium methoxide solution (20 mL, 2%) was refluxed for 1 h on a water bath at 70 °C with stirring. The reaction mixture was evaporated under reduced pressure, the obtained residue was dissolved in CH~2~Cl~2~, washed with H~2~O, 10 mL 1 N HCl and then with water. The solvent was dried over anhydrous CaCl~2~, evaporated under reduced pressure, and the obtained product was crystallized to afford from the proper solvents to afford the corresponding ethyl thienopyridinecarboxylates **6a**--**c**, respectively.

*Ethyl 3-amino-6-(2-chloro-6-ethoxypyridin-4-yl)-4-(4-fluorophenyl)thieno\[2,3-b\]pyridine-2-carboxyl-ate* (**6a**). IR (KBr, cm^−1^): ν 3443 (NH~2~), 1742 (C=O, ester); ^1^H-NMR: δ 1.30, 1.34 (2t, 6H, 2 CH~3~), 3.72, 4.06 (2q, 4H, 2 CH~2~), 4.36 (s, 2H, NH~2~ exchangeable with D~2~O), 7.24--7.75 (m, 6H, 4 Ph-H + 2 pyr-H), 8.35 (s, 1H, pyr-5\'-H); ^13^C-NMR: 13.95, 14.16, 60.24, 64.18, 101.58, 103.02, 115.16, 118.35, 120.76, 122.15, 128.66, 132.64, 134.12, 145.72, 149.65, 151.64, 154.57, 155.75, 160.12, 162.65, 164.12; MS, *m/z* (%): 472 \[M^+^,26\], 317 \[100, base peak\]; Elemental analysis for C~23~H~19~ClFN~3~O~3~S (471.93): calcd.: C, 58.54; H, 4.06; Cl, 7.51; N, 8.90; S, 6.79. found: C, 58.48; H, 4.00; Cl, 7.45; N, 8.86; S, 6.71.

*Ethyl 3-amino-6-(2-chloro-6-ethoxypyridin-4-yl)-4-(4-chlorophenyl)thieno\[2,3-b\]pyridine-2-carboxyl-ate* (**6b**). IR (KBr, cm^−1^): ν 3452 (NH~2~), 1737 (C=O, ester); ^1^H-NMR: δ 1.26, 1.31 (2t, 6H, 2 CH~3~), 3.78, 4.10 (2q, 4H, 2 CH~2~), 4.48 (s, 2H, NH~2~ exchangeable with D~2~O), 7.24--7.82 (m, 6H, 4 Ph-H + 2 pyr-H), 8.72 (s, 1H, pyr-5\'-H); ^13^C-NMR: 14.08, 14.25, 60.15, 64.10, 100.42, 103.64, 118.05, 121.16, 122.25, 127.66, 128.44, 133.45, 133.95, 134.50, 146.02, 149.75, 151.18, 154.65, 156.05, 159.64, 164.15; MS, *m/z* (%): 488 \[M^+^,8\], 332 \[100, base peak\]; Elemental analysis for C~23~H~19~Cl~2~N~3~O~3~S (488.38): calcd.: C, 56.56; H, 3.92; Cl, 14.52; N, 8.60; S, 6.57. found: C, 56.50; H, 3.88; Cl, 14.46; N, 8.55; S, 6.50.

*Ethyl 3-amino-6-(2-chloro-6-ethoxypyridin-4-yl)-4-(2,4-dichlorophenyl)thieno\[2,3-b\]pyridine-2-carboxylate* (**6c**). IR (KBr, cm^−1^): ν 3456 (NH~2~), 1735 (C=O, ester); ^1^H-NMR: δ 1.30, 1.33 (2t, 6H, 2 CH~3~), 3.82, 4.15 (2q, 4H, 2 CH~2~), 4.56 (s, 2H, NH~2~ exchangeable with D~2~O), 7.08--7.68 (m, 5H, 3 Ph-H + 2 pyr-H), 8.62 (s, 1H, pyr-5\'-H); ^13^C-NMR: 14.12, 14.26, 59.98, 64.32, 100.86, 102.72, 118.02, 121.06, 122.00, 126.16, 128.87, 129.36, 132.18, 134.05, 135.44, 136.74, 145.64, 149.85, 151.38, 154.72, 155.43, 160.04, 164.25; MS, *m/z* (%): 523 \[M^+^,6\], 177 \[100, base peak\]; Elemental analysis for C~23~H~18~Cl~3~N~3~O~3~S (522.83): calcd.: C, 52.84; H, 3.47; Cl, 20.34; N, 8.04; S, 6.13. found: C, 52.77; H, 3.42; Cl, 20.30; N, 7.97; S, 6.08.

*3-Amino-6-(2-chloro-6-ethoxypyridin-4-yl)-4-(substituted-phenyl)thieno\[2,3-b\]pyridine-2-carbox-amides* **7a**--**c**. A current of ammonia gas was passed through a suspension of **6a**--**c** (1 mmol) in absolute ethanol (100 mL), at 0 °C till saturation. The reaction mixture was left overnight at −4 °C, evaporated under reduced pressure, the residue obtained was triturated with *n*-hexane, the formed solid was filtered off, washed with water and crystallized from the proper solvents to give the corresponding thienopyridine carboxamides **7a**--**c**, respectively.

*3-Amino-6-(2-chloro-6-ethoxypyridin-4-yl)-4-(4-fluorophenyl)thieno\[2,3-b\]pyridine-2-carboxamide* (**7a**). IR (KBr, cm^−1^): ν 3460--3380 (NH~2~), 1675 (C=O, amide); ^1^H-NMR: δ 1.32 (t, 3H, CH~3~), 3.85 (q, 2H, CH~2~), 4.46, 6.85 (2s, 4H, 2 NH~2~ exchangeable with D~2~O), 7.12--7.68 (m, 6H, 4 Ph-H + 2 pyr-H), 8.56 (s, 1H, pyr-5\'-H); ^13^C-NMR: 14.06, 64.28, 100.96, 102.22, 115.36, 120.82, 122.45, 128.37, 128.46, 132.84, 137.15, 145.82, 149.65, 152.00, 154.74, 157.75, 161.55, 162.76, 164.30; MS, *m/z* (%): 443 \[M^+^,8\], 332 \[100, base peak\]; Elemental analysis for C~21~H~16~ClFN~4~O~2~S (442.89): calcd.: C, 56.95; H, 3.64; Cl, 8.00; N, 12.65; S, 7.24. found: C, 56.90; H, 3.60; Cl, 7.940; N, 12.60; S, 7.19.

*3-Amino-6-(2-chloro-6-ethoxypyridin-4-yl)-4-(4-chlorophenyl)thieno\[2,3-b\]pyridine-2-carboxamide* (**7b**). ν 3456--3378 (NH~2~), 1672 (C=O, amide); ^1^H-NMR: δ 1.30 (t, 3H, CH~3~), 3.82 (q, 2H, CH~2~), 4.44, 6.88 (2s, 4H, 2 NH~2~ exchangeable with D~2~O), 7.32--7.68 (m, 6H, 4 Ph-H + 2 pyr-H), 8.68 (s, 1H, pyr-5\'-H); ^13^C-NMR: 13.68, 64.12, 100.00, 102.04, 121.24, 122.12, 127.85, 128.38, 128.55, 134.05, 135.15, 137.05, 146.12, 149.65, 151.00, 154.36, 156.14, 161.42, 164.04; MS, *m/z* (%): 459 \[M^+^,25\], 287 \[100, base peak\]; Elemental analysis for C~21~H~16~Cl~2~N~4~O~2~S (459.34): calcd.: C, 54.91; H, 3.51; Cl, 15.44; N, 12.20; S, 6.98. found: C, 54.86; H, 3.45; Cl, 15.39; N, 12.16; S, 6.92.

*3-Amino-6-(2-chloro-6-ethoxypyridin-4-yl)-4-(2,4-dichlorophenyl)thieno\[2,3-b\]pyridine-2-carboxamide* (**7c**). IR (KBr, cm^−1^): ν 3456 (NH~2~), 1735 (C=O, ester); ^1^H-NMR: δ 1.28 (t, 3H, CH~3~), 3.86 (q, 2H, CH~2~), 4.54, 6.76 (2s, 4H, 2 NH~2~ exchangeable with D~2~O), 7.12--7.73 (m, 5H, 3 Ph-H + 2 pyr-H), 8.48 (s, 1H, pyr-5\'-H); ^13^C-NMR: 14.12, 64.33, 101.04, 102.84, 121.32, 122.40, 126.24, 128.65, 128.75, 129.72, 132.32, 135.12, 136.66, 137.22, 145.56, 149.55, 151.22, 154.44, 157.12, 161.26, 164.57; MS, *m/z* (%): 494 \[M^+^,12\], 320 \[100, base peak\]; Elemental analysis for C~21~H~15~Cl~3~N4O~2~S (493.79): calcd.: C, 51.08; H, 3.06; Cl, 21.54; N, 11.35; S, 6.49. found: C, 51.00; H, 3.00; Cl, 21.50; N, 11.30; S, 6.44.

*7-(2-Chloro-6-ethoxypyridin-4-yl)-9-(substituted-phenyl)-2-methyl-4H-pyrido\[3\',2\':4,5\]thieno\[3,2-d\]-\[1,3\]-oxazin-4-ones* **9a**--**c**. A mixture of **6a**--**c** (1 mmol) in ethanolic NaOH (100 mL, 5%) was heated under reflux for 4 h. The solvent was evaporated under reduced pressure, the obtained sodium salt **8a**--**c** was dissolved in acetic anhydride (100 mL) and refluxed it for 6 h. The reaction mixture was concentrated and allowed to cool, poured onto ice water, the obtained solid was collected by filtration, washed with water, dried and crystallized from the proper solvents to afford the corresponding thienooxazinopyridine derivatives **9a**--**c**, respectively.

*7-(2-Chloro-6-ethoxypyridin-4-yl)-9-(4-fluorophenyl)-2-methyl-4H-pyrido\[3\',2\':4,5\]thieno\[3,2-d\]-\[1,3\]oxazin-4-one* (**9a**). IR (KBr, cm^−1^): ν 1750 (C=O); ^1^H-NMR: δ 1.30 (t, 3H, CH~3~), 2.03 (s, 3H, CH~3~), 3.78 (q, 2H, CH~2~), 7.04--7.58 (m, 6H, 4 Ph-H + 2 pyr-H), 8.62 (s, 1H, pyr-5\'-H); ^13^C-NMR: 14.10, 18.98, 64.30, 100.86, 101.68, 116.02, 120.80, 125.85, 128.42, 132.78, 134.46, 135.35, 145.72, 150.05, 151.75, 154.90, 155.25 158.62, 162.70, 164.08, 165.25; MS, *m/z* (%): 468 \[M^+^,6\], 217 \[100, base peak\]; Elemental analysis for C~23~H~15~ClFN~3~O~3~S (467.89): calcd.: C, 59.04; H, 3.23; Cl, 7.58; N, 8.98; S, 6.85. found: C, 58.96; H, 3.18; Cl, 7.52; N, 8.90; S, 6.80.

*7-(2-Chloro-6-ethoxypyridin-4-yl)-9-(4-chlorophenyl)-2-methyl-4H-pyrido\[3\',2\':4,5\]thieno\[3,2-d\]-\[1,3\]oxazin-4-one* (**9b**). IR (KBr, cm^−1^): ν 1745 (C=O); ^1^H-NMR: δ 1.28 (t, 3H, CH~3~), 2.01 (s, 3H, CH~3~), 3.89 (q, 2H, CH~2~), 7.23--7.65 (m, 6H, 4 Ph-H + 2 pyr-H), 8.42 (s, 1H, pyr-5\'-H); ^13^C-NMR: 14.08, 21.60, 64.18, 100.55, 101.45, 121.12, 125.68, 128.12, 128.96, 133.05, 134.58, 135.32, 135.72, 145.92, 149.75, 151.84, 154.86, 155.14, 158.70, 164.12, 165.18; MS, *m/z* (%): 484 \[M^+^,15\], 156 \[100, base peak\]; Elemental analysis for C~23~H~15~Cl~2~N~3~O~3~S (484.35): calcd.: C, 57.03; H, 3.12; Cl, 14.64; N, 8.68; S, 6.62. found: C, 56.95; H, 3.10; Cl, 14.60; N, 8.63; S, 6.58.

*7-(2-Chloro-6-ethoxypyridin-4-yl)-9-(2,4-dichlorophenyl)-2-methyl-4H-pyrido\[3\',2\':4,5\]thieno\[3,2-d\]-\[1,3\]oxazin-4-one* (**9c**). IR (KBr, cm^−1^): ν 1750 (C=O); ^1^H-NMR: δ 1.30 (t, 3H, CH~3~), 2.00 (s, 3H, CH~3~), 3.82 (q, 2H, CH~2~), 7.21--7.68 (m, 5H, 3 Ph-H + 2 pyr-H), 8.54 (s, 1H, pyr-5\'-H); ^13^C-NMR: 14.10, 19.18, 64.22, 100.28, 101.15, 121.16, 125.56, 126.46, 128.58, 129.80, 132.44, 134.34, 135.18, 135.45, 136.73, 145.88, 149.72, 151.69, 154.78, 155.18, 159.06, 164.18, 165.32; MS, *m/z* (%): 519 \[M^+^,8\], 320 \[100, base peak\]; Elemental analysis for C~23~H~14~Cl~3~N~3~O~3~S (518.79): calcd.: C, 53.25; H, 2.72; Cl, 20.50; N, 8.10; S, 6.18. found: C, 53.18; H, 2.68; Cl, 20.45; N, 8.00; S, 6.12.

*7-(2-Chloro-6-ethoxypyridin-4-yl)-9-(substituted-phenyl)-2-methylpyrido\[3\',2\':4,5\]thieno\[3,2-d\]-pyrimidin-4(3H)-ones* **10a**--**c**

A mixture of **9a**--**c** (1 mmol) and ammonium acetate (0.6 g, 8 mmol) in glacial acetic acid (100 mL) was heated under reflux for 6 h. The reaction mixture was evaporated under reduced pressure, the residue was triturated with cooled water, the solid formed was collected by filtration, washed with water, dried and crystallized from the proper solvents to afford the corresponding thienopyrimidino-pyridine 0.30 g (70%) **10a**--**c**, respectively.

*7-(2-Chloro-6-ethoxypyridin-4-yl)-9-(4-fluorophenyl)-2-methylpyrido\[3\',2\':4,5\]thieno\[3,2-d\]-pyrimidin-4(3H)-one* (**10a**). IR (KBr, cm^−1^): ν 3420 (NH), 1650 (C=O); ^1^H-NMR: δ 1.28 (t, 3H, CH~3~), 2.32 (s, 3H, CH~3~), 3.86 (q, 2H, CH~2~), 7.12--7.64 (m, 6H, 4 Ph-H + 2 pyr-H), 8.58 (s, 1H, pyr-5\'-H), 9.26 (s, 1H, NH exchangeable with D~2~O); ^13^C-NMR: 14.08, 24.98, 64.42, 101.02, 102.54, 116.15, 121.04, 126.14, 128.85, 132.86, 136.76, 137.05, 145.88, 150.15, 151.98, 154.10, 154.86, 157.25, 160.03, 162.99, 164.28; MS, *m/z* (%): 467 \[M^+^,18\], 156 \[100, base peak\]; Elemental analysis for C~23~H~16~ClFN~4~O~2~S (466.91): calcd.: C, 59.16; H, 3.45; Cl, 7.59; N, 12.00; S, 6.87. found: C, 59.10; H, 3.38; Cl, 7.52; N, 11.94; S, 6.83.

*7-(2-Chloro-6-ethoxypyridin-4-yl)-9-(4-chlorophenyl)-2-methylpyrido\[3\',2\':4,5\]thieno\[3,2-d\]-pyrimidin-4(3H)-one* (**10b**). IR (KBr, cm^−1^): ν 3438 (NH), 1649 (C=O); ^1^H-NMR: δ 1.31 (t, 3H, CH~3~), 2.24 (s, 3H, CH~3~), 3.78 (q, 2H, CH~2~), 7.33--7.72 (m, 6H, 4 Ph-H + 2 pyr-H), 8.62 (s, 1H, pyr-5\'-H), 9.32 (s, 1H, NH exchangeable with D~2~O); ^13^C-NMR: 13.98, 25.04, 64.53, 100.12, 101.36, 121.13, 126.45, 128.15, 129.05, 133.76, 135.99, 136.88, 145.76, 146.05, 149.85, 151.90, 154.16, 154.92, 157.48, 159.73, 164.36; MS, *m/z* (%): 483 \[M^+^,18\], 326 \[100, base peak\]; Elemental analysis for C~23~H~16~Cl~2~N~4~O~2~S (483.36): calcd.: C, 57.15; H, 3.34; Cl, 14.67; N, 11.59; S, 6.63. found: C, 57.10; H, 3.28; Cl, 14.62; N, 11.53; S, 6.58.

*7-(2-Chloro-6-ethoxypyridin-4-yl)-9-(2,4-dichlorophenyl)-2-methylpyrido\[3\',2\':4,5\]thieno\[3,2-d\]-pyrimidin-4(3H)-one* (**10c**). IR (KBr, cm^−1^): ν 3465 (NH), 1653 (C=O); ^1^H-NMR: δ 1.26 (t, 3H, CH~3~), 2.12 (s, 3H, CH~3~), 3.80 (q, 2H, CH~2~), 7.21--7.70 (m, 5H, 3 Ph-H + 2 pyr-H), 8.72 (s, 1H, pyr-5\'-H), 9.48 (s, 1H, NH exchangeable with D~2~O); ^13^C-NMR: 13.92, 24.87, 64.42, 99.96, 101.02, 120.33, 126.32, 126.64, 128.36, 129.72, 132.88, 135.09, 136.64, 136.84, 145.86, 146.13, 149.77, 151.92, 153.96, 154.66, 157.68, 160.02, 164.48; MS, *m/z* (%): 518 \[M^+^,5\], 145 \[100, base peak\]; Elemental analysis for C~23~H~15~Cl~3~N~4~O~2~S (517.81): calcd.: C, 53.35; H, 2.92; Cl, 20.54; N, 10.82; S, 6.19. found: C, 53.30; H, 2.87; Cl, 20.50; N, 10.79; S, 6.14.

*7-(2-Chloro-6-ethoxypyridin-4-yl)-9-(4-fluorophenyl)-2,3-dimethylpyrido\[3\',2\':4,5\]thieno\[3,2-d\]pyrimidin-4(3H)-ones* **11a**--**c**. A solution of **10a**--**c** (1 mmol) in DMF (20 mL) was stirred with anhydrous K~2~CO~3~ (0.19 g, 1 mmol) for 10 min at room temperature, then methyl iodide (0.28 g, 2 mmol) in DMF (5 mL) were added. The reaction mixture was heated at 60 °C for 4 h, after cooling, poured into ice water, and the formed precipitate was filtered off, washed with water, dried and crystallized from the proper solvents to afford the corresponding thieno*-N*-methylpyrimidinopyridines **11a**--**c**, respectively.

*7-(2-Chloro-6-ethoxypyridin-4-yl)-9-(4-fluorophenyl)-2,3-dimethylpyrido\[3\',2\':4,5\]thieno\[3,2-d\]pyrimidin-4(3H)-one* (**11a**). IR (KBr, cm^−1^): ν 1668 (C=O); ^1^H-NMR: δ 1.28 (t, 3H, CH~3~), 2.32, 3.10 (2s, 6H, 2 CH~3~), 3.78 (q, 2H, CH~2~), 7.08--7.68 (m, 6H, 4 Ph-H + 2 pyr-H), 8.62 (s, 1H, pyr-5\'-H); ^13^C-NMR: 14.00, 22.14, 26.06, 64.15, 100.10, 101.32, 116.18, 120.34, 126.34, 128.95, 132.90, 136.42, 145.76, 146.15, 149.85, 151.80, 154.02, 154.77, 157.36, 159.63, 162.76, 164.30; MS, *m/z* (%): 481 \[M^+^,4\], 98 \[100, base peak\]; Elemental analysis for C~24~H~18~ClFN~4~O~2~S (480.94): calcd.: C, 59.94; H, 3.77; Cl, 7.37; N, 11.65; S, 6.67. found: C, 59.88; H, 3.72; Cl, 7.33; N, 11.60; S, 6.61.

*7-(2-Chloro-6-ethoxypyridin-4-yl)-9-(4-chlorophenyl)-2,3-dimethylpyrido\[3\',2\':4,5\]thieno\[3,2-d\]-pyrimidin-4(3H)-one* (**11b**). IR (KBr, cm^−1^): ν 1670 (C=O); ^1^H-NMR: δ 1.29 (t, 3H, CH~3~), 2.18, 3.06 (2s, 6H, 2 CH~3~), 3.82 (q, 2H, CH~2~), 7.28--7.68 (m, 6H, 4 Ph-H + 2 pyr-H), 8.78 (s, 1H, pyr-5\'-H); ^13^C-NMR: 13.86, 22.00, 26.28, 64.14, 99.58, 100.12, 120.56, 126.76, 128.00, 128.95, 133.45, 135.85, 136.56, 145.32, 146.75, 149.80, 150.87, 153.78, 154.65, 157.45, 160.02, 164.28; MS, *m/z* (%): 497 \[M^+^,19\], 162 \[100, base peak\]; Elemental analysis for C~24~H~18~Cl~2~N~4~O~2~S (497.39): calcd.: C, 57.95; H, 3.65; Cl, 14.26; N, 11.26; S, 6.45. found: C, 57.90; H, 3.59; Cl, 14.22; N, 11.20; S, 6.40.

*7-(2-Chloro-6-ethoxypyridin-4-yl)-9-(2,4-dichlorophenyl)-2,3-dimethylpyrido\[3\',2\':4,5\]thieno\[3,2-d\]-pyrimidin-4(3H)-one* (**11c**). IR (KBr, cm^−1^): ν 1667 (C=O); ^1^H-NMR: δ 1.28 (t, 3H, CH~3~), 2.22, 2.96 (2s, 6H, 2 CH~3~), 3.80 (q, 2H, CH~2~), 7.24--7.70 (m, 5H, 3 Ph-H + 2 pyr-H), 8.65 (s, 1H, pyr-5\'-H); ^13^C-NMR: 13.90, 22.01, 26.48, 64.08, 99.86, 100.09, 120.60, 126.45, 126.58, 128.25, 129.52, 132.66, 135.14, 136.60, 136.78, 145.42, 146.78, 149.82, 151.14, 153.88, 154.72, 157.48, 159.72, 164.20; MS, *m/z* (%): 532 \[M^+^,19\], 252 \[100, base peak\]; Elemental analysis for C~24~H~17~Cl~3~N4O~2~S (531.84): calcd.: C, 54.20; H, 3.22; Cl, 20.00; N, 10.53; S, 6.03. found: C, 54.15; H, 3.16; Cl, 19.85; N, 10.48; S, 6.00.

3.2. Antimicrobial Screening Media {#sec3dot2-molecules-17-13642}
----------------------------------

The following media were used:PDA medium: this medium was used for fungi cultivation. It consists of 4 g dextrose/L potatoes extract.Czapek Dox medium: it consists of 10 g glucose, 2 g KNO~3~, 1g K~2~HPO~4~, 0.5 g KCl, 0.5 g MgSO~4~, and 0.05 g ferrous sulphate/L distilled water. This medium is specialized for bacteria cultivation.Medium 3: it consists of 10 glucose, 5 g peptone, 3 yeast extract, and 3 malt extract. It was used for yeast cultivation.

4. Conclusions {#sec4-molecules-17-13642}
==============

A series of newly compounds **3**--**11** were prepared using citrazinic acid (2,6-dihydroxyisonicotinic acid) as a starting material. The obtained derivatives were screening as antimicrobial and antifungal agents. Four of the synthesized compounds **5a**, **7b**, **9b** and **10b** exhibited potent antibacterial and antifungal bioactivity compared with streptomycin and fusidic acid used as reference drugs. The other tested compounds were found to exhibit moderate to low antibacterial activity. On the other hand when higher concentrations (3× and 4×) of compound **9a**, which exhibited a moderate antibacterial activity, were used, this compound exhibited very good antibacterial activity. While different concentrations of compounds **5a** and **10a** exhibited a very good antifungal activity (2× and 3×).

The authors extend their appreciation to the Deanship of Scientific Research at King Saud University for funding the work through the research group project No. RGP-VPP-172.

*Sample Availability*: Samples of the compounds are available from the authors.

Schemes and Tables
==================

![Synthetic Pathway for Compound **3**--**7**.](molecules-17-13642-sch001){#molecules-17-13642-sch001}

![Synthetic Pathway for Compound **9**--**11**.](molecules-17-13642-sch002){#molecules-17-13642-sch002}

molecules-17-13642-t001_Table 1

###### 

Melting points, crystallization solvents, yields, molecular formulae and molecular weights of compounds **3**--**7**.

  Comp. No.   X    Y    Yield (%)   M.p. (°C)   Cryst. Solv.       Molecular Formula (Mol. Wt.)
  ----------- ---- ---- ----------- ----------- ------------------ -----------------------------------
  **3a**      F    H    86          185--187    EtOH               C~16~H~13~ClFNO~2~ (505.73)
  **3b**      Cl   H    82          155--157    EtOH               C~16~H~13~Cl~2~NO~2~ (322.19)
  **3c**      Cl   Cl   85          203--205    EtOH               C~16~H~12~Cl~3~NO~2~ (356.63)
  **4a**      F    H    65          192--194    DMF/H~2~O (2:1)    C~19~H~13~ClFN~3~OS (385.84)
  **4b**      Cl   H    58          206--208    AcOH/H~2~O (2:1)   C~19~H~13~Cl~2~N~3~OS (402.30)
  **4c**      Cl   Cl   70          225--227    DMF/H~2~O (2:1)    C~19~H~12~Cl~3~N~3~OS (436.74)
  **5a**      F    H    78          198--200    EtOH/Ether (2:1)   C~23~H~19~ClFN~3~O~3~S (471.93)
  **5b**      Cl   H    76          189--191    EtOH/Ether (2:1)   C~23~H~19~Cl~2~N~3~O~3~S (488.39)
  **5c**      Cl   Cl   69          245--257    EtOH/Ether (2:1)   C~23~H~18~Cl~3~N~3~O~3~S (522.83)
  **6a**      F    H    65          176--178    Dioxane            C~23~H~19~ClFN~3~O~3~S (471.93)
  **6b**      Cl   H    70          214--216    EtOH               C~23~H~19~Cl~2~N~3~O~3~S (488.39)
  **6c**      Cl   Cl   58          235--237    DMF/EtOH (2:1)     C~23~H~18~Cl~3~N~3~O~3~S (522.83)
  **7a**      F    H    86          200--202    MeOH               C~21~H~16~ClFN~4~O~2~S (442.89)
  **7b**      Cl   H    85          228--230    AcOH               C~21~H~16~Cl~2~N~4~O~2~S (459.35)
  **7c**      Cl   Cl   84          256--258    AcOH/H~2~O (2:1)   C~21~H~15~Cl~3~N~4~O~2~S (493.79)

molecules-17-13642-t002_Table 2

###### 

Melting points, crystallization solvents, yields, molecular formulae and molecular weights of compounds **9**--**11**.

  Comp. No.   X    Y    Yield (%)   M.p. (°C)   Cryst. Solv.       Molecular Formula (Mol. Wt.)
  ----------- ---- ---- ----------- ----------- ------------------ -----------------------------------
  **9a**      F    H    75          195--197    EtOH               C~23~H~15~ClFN~3~O~3~S (467.90)
  **9b**      Cl   H    68          214--216    AcOH               C~23~H~15~Cl~2~N~3~O~3~S (484.35)
  **9c**      Cl   Cl   60          282--284    DMF/H~2~O (2:1)    C~23~H~14~Cl~3~N~3~O~3~S (518.80)
  **10a**     F    H    80          178--180    AcOH/H~2~O (2:1)   C~23~H~16~ClFN~4~O~2~S (466.92)
  **10b**     Cl   H    72          188--190    AcOH/H~2~O (2:1)   C~23~H~16~Cl~2~N~4~O~2~S (483.37)
  **10c**     Cl   Cl   65          256--258    DMF/H~2~O (2:1)    C~23~H~15~Cl~3~N~4~O~2~S (517.81)
  **11a**     F    H    78          186--188    AcOH/H~2~O (2:1)   C~24~H~18~ClFN4O~2~S (480.94)
  **11b**     Cl   H    66          200--202    AcOH               C~24~H~18~Cl~2~N~4~O~2~S (497.40)
  **11c**     Cl   Cl   72          264--266    DMF/H~2~O (2:1)    C~24~H~17~Cl~3~N~4~O~2~S (531.84)

molecules-17-13642-t003_Table 3

###### 

Antimicrobial activities of the newly synthesized compounds **3**--**11**.

  -------------------------------------------------------------------------------------
  Comp. No.          Fungi   Yeast   \           Bacteria                            
                                     *Str. sp*                                       
  ------------------ ------- ------- ----------- ---------- ---- ---- ---- ---- ---- --
  **3a**             12      12      12          11         13   14   14   14   13   

  **3b**             12      12      10          11         9    8    7    9    11   

  **3c**             8       10      9           11         12   12   12   11   14   

  **4a**             10      12      11          11         13   11   10   12   11   

  **4b**             11      12      13          11         14   13   11   12   12   

  **4c**             10      12      12          13         13   12   10   12   11   

  **5a**             17      16      16          17         22   23   24   23   21   

  **5b**             4       5       4           3          7    8    7    9    8    

  **5c**             13      12      12          13         11   13   12   10   9    

  **6a**             10      13      10          11         21   20   21   23   23   

  **6b**             8       8       6           7          11   12   13   13   12   

  **6c**             12      13      13          12         13   11   13   12   13   

  **7a**             13      12      12          13         11   13   12   10   9    

  **7b**             7       5       8           9          6    12   13   13   12   

  **7c**             12      13      11          13         12   8    8    6    7    

  **9a**             12      10      11          11         20   20   21   19   20   

  **9b**             19      20      19          19         11   13   12   10   9    

  **9c**             10      11      11          12         10   11   10   12   11   

  **10a**            15      16      13          14         11   11   12   12   13   

  **10b**            23      22      22          20         11   23   22   24   23   

  **10c**            11      10      12          11         11   10   12   11   11   

  **11a**            13      12      12          13         11   13   12   10   9    

  **11b**            10      12      11          11         13   11   10   12   11   

  **11c**            13      11      10          12         11   10   12   11   11   

  **Streptomycin**   \-      \-      \-          \-         21   22   21   22   21   

  **Fusidic acid**   17      17      18          18         \-   \-   \-   \-   \-   
  -------------------------------------------------------------------------------------

*A.n: Aspergillus niger*; *Pen. sp: Penicillium sp*; *C. a: Candida albican; Str. sp: Streptomyces sp*; *R.i: Rhodotorula ingeniosa*; *B.s: Bacillus subtilis*; *S.l: Streptococcus lactis*; *E.c: Escherichia coli*; *P. sp: Pseudomonas sp.*

molecules-17-13642-t004_Table 4

###### 

Antibacterial activity of compound **9a** at different concentrations.

  -----------------------------------------------------------
  \           \       \             Bacteria             
  Comp. No.   Conc.   *Strep. sp*                        
  ----------- ------- ------------- ---------- ---- ---- ----
  **9a**      1×      20            20         21   19   20

  2×          23      23            22         23   22   

  3×          25      24            24         24   26   

  4×          25      25            27         25   26   
  -----------------------------------------------------------

Where × = 10 μg.

molecules-17-13642-t005_Table 5

###### 

Antifungal activity of compounds **5a** and **10a** at different concentrations.

  Comp. No.   Conc.   Fungi             
  ----------- ------- ------- ---- ---- ----
  **5a**      1×      17      16   16   17
  2×          18      18      19   19   
  3×          19      20      20   21   
  4×          20      22      20   21   
  **10a**     1×      15      16   13   14
  2×          16      18      18   17   
  3×          18      20      20   20   
  4×          20      22      20   21   

Where × = 10 μg.
